中醫現代研究資料庫
首頁 / 癌因性疼痛 / RoB 2 偏誤風險評讀

COCHRANE ROB 2 · 偏誤風險評讀

Constant-Murley 分數(療程結束)

← 回到「癌因性疼痛」的圖表
總體判斷 OVERALL?Some concerns(有些疑慮)
Domain 與 overall 判斷由程式依 Cochrane RoB 2 官方演算法計算;AI 只負責回答下方各訊號問題。符號:+ 低風險、? 有些疑慮、- 高風險(不只靠顏色)。
風險偏誤紅綠燈
中文摘要(給一般讀者)
這篇論文的偏誤風險與 limitation
本研究為前瞻、開放標籤的平行組 RCT(針灸 vs 常規照護 usual care),主要結局為 4 週療程結束時的 Constant-Murley 複合分數(ITT,針灸優於對照 +11.2 分、P=.008)。隨機化健全:分層+隨機長度區組+電腦化資料庫確保完整分配隱匿;雖有性別、基線分數與用藥的偶發不均衡,但已以共變數校正,未暗示隨機化問題。因開放標籤,病人與施治者皆知分組(無法盲化為此療法本質);分析採 ITT,故指派效果的偏離風險低。缺失資料約 17%(70 隨機、58 可評估),但作者以多重插補(含保守假設)做敏感度分析結果幾乎不變,缺失偏誤風險受控。結局測量為本篇關鍵:主要量表由盲化第三方研究人員評估(客觀的活動度/肌力尤佳),但複合分數含病人自陳的疼痛與 ADL 子量表,作者自承易受未設盲者偏誤回報影響,故 4.3/4.4 取保守 PY;惟僅取純客觀成分重分析仍顯著(10.1 分、P=.037),顯示效果非單由知情自陳驅動,4.5 判 PN,Domain 4 傾向『部分疑慮』。選擇性報告方面,主要結局、主分析與樣本數事前明訂且為登錄試驗,報告透明,風險低。整體而言本結局主要偏誤來源為開放標籤下半主觀複合結局的測量疑慮,其餘面向偏誤風險低。
詳細評讀(給專業讀者)

Domain 1:隨機化過程 — 判斷:Low

偏誤來源:隨機分組的過程——分配序列是否隨機產生、是否隱蔽到分組為止、基線(第一期開始時)是否平衡。
1.1 Was the allocation sequence random?
分配序列是否隨機產生?
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?
分配是否隱蔽到分組為止?
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?
(第一期開始時)基線差異是否暗示隨機化有問題?

Domain 2:偏離預定介入 — 判斷:Low

偏誤來源:實際執行時偏離預定的介入——盲性如何、是否依「隨機分到的組別」分析(ITT)。
2.1 Were participants aware of their assigned intervention during the trial?
參與者是否(在每一期)知道自己的分組?
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?
照護/執行者是否(在每一期)知道分組?
2.3 Were there deviations from the intended intervention that arose because of the trial context?
是否因試驗情境造成偏離?
2.4 Were these deviations likely to have affected the outcome?
這些偏離是否可能影響結局?
2.5 Were these deviations from intended intervention balanced between groups?
這些偏離在兩組間是否平衡?
2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?
是否用了適當分析(ITT)?
2.7 Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?
未依隨機分組分析,是否可能對結果造成重大影響?

Domain 3:缺失結局資料 — 判斷:Low

偏誤來源:結局資料缺失——是否幾乎所有人都有資料、缺失是否可能與病情(結局真實值)相關。
3.1 Were data for this outcome available for all, or nearly all, participants randomized?
是否幾乎所有受試者都有此結局的資料?
3.2 Is there evidence that the result was not biased by missing outcome data?
是否有證據顯示結果未受缺失資料偏誤?
3.3 Could missingness in the outcome depend on its true value?
缺失是否可能取決於結局真實值?
3.4 Is it likely that missingness in the outcome depended on its true value?
缺失是否很可能取決於結局真實值?

Domain 4:結局測量 — 判斷:Some concerns

偏誤來源:結局的測量——測量工具是否恰當、評估者是否盲化、評估是否可能受分組知情影響。
4.1 Was the method of measuring the outcome inappropriate?
結局測量方法是否不適當?
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?
(每一序列內)結局測量是否可能因介入而異?
4.3 Were outcome assessors aware of the intervention received by study participants?
結局評估者是否知道受試者接受的介入?
4.4 Could assessment of the outcome have been influenced by knowledge of intervention received?
結局評估是否可能受介入知情影響?
4.5 Is it likely that assessment of the outcome was influenced by knowledge of intervention received?
結局評估是否很可能受介入知情影響?

Domain 5:選擇性報告 — 判斷:Low

偏誤來源:選擇性報告結果——是否依事前訂定的分析計畫分析、有無從多個結果中挑選有利者報告(交叉另含:是否因偵測到殘留而只報第一期)。
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?
是否依事前訂定(取得未盲化資料前定版)的分析計畫分析?
5.2 Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?
此數值結果是否可能依結果,從多個量表/定義/時間點中選出?
5.3 Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible analyses of the data?
此數值結果是否可能依結果,從多種分析中選出?
本評讀依 Cochrane Risk of Bias 2 (RoB 2) 工具,針對「單一結果 × 單一效應」評估。限制:僅依論文全文判讀(無完整研究計畫書/統計分析計畫),故 Domain 5(選擇性報告)常為「資訊不足」。AI 僅回答訊號問題,domain 與 overall 由官方決策表程式計算。